# Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

> **NCT00848029** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 240 (actual)

## Conditions studied

- Pre-pandemic Influenza Vaccine

## Interventions

- **BIOLOGICAL:** Monovalent inactivated influenza vaccine

## Key facts

- **NCT ID:** NCT00848029
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848029, "Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00848029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*